BS_HE57E1RP
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 6
- os_event
- true
- age_years
- 9.597
- sex
- M
- race
- White
- umap1_2d
- 3.207533319
- umap2_2d
- 0.17008821
- umap1_3d
- -0.249004224
- umap2_3d
- -2.287470492
- umap3_3d
- -0.384257589
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.560
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.490
- ANGIOGENESIS+0.380
- MTORC1_SIGNALING+0.360
- INTERFERON_ALPHA_RESPONSE+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.250
- DNA_REPAIR+0.220
Top 10 suppressed
- PROTEIN_SECRETION-0.370
- HEDGEHOG_SIGNALING-0.270
- PANCREAS_BETA_CELLS-0.190
- HEME_METABOLISM-0.180
- APICAL_JUNCTION-0.160
- APICAL_SURFACE-0.140
- BILE_ACID_METABOLISM-0.120
- HYPOXIA-0.120
- PI3K_AKT_MTOR_SIGNALING-0.120
- UV_RESPONSE_DN-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0549 | Med | Medulloblastoma | 0.850 |
| 2 | TCGA-QK-A6IG-01A-11R-A31N-07 | — | — | 0.822 |
| 3 | BS_R439VVPK | Med | Medulloblastoma | 0.816 |
| 4 | MDT-AP-2391 | Med | Medulloblastoma | 0.805 |
| 5 | MDT-AP-0509 | Med | Medulloblastoma | 0.795 |
| 6 | MDT-AP-0203 | Med | Medulloblastoma | 0.779 |
| 7 | E1B8B320-25EE-4B2C-B705-AB50C3EF5E29 | — | — | 0.770 |
| 8 | SRR12475159 | — | — | 0.770 |
| 9 | BS_QX12J6W1 | ATRT | — | 0.769 |
| 10 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |